Roxithromycin related substance as well as preparation method and application thereof

By preparing the roxithromycin impurity K, the problem of the unclear structure of the roxithromycin impurity was solved, and the preparation of high-purity roxithromycin impurity was achieved, which improved the safety of medication and provided high-precision analysis tools.

CN118994281APending Publication Date: 2024-11-22ZHEJIANG GUOBANG PHARMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410800700.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-20
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The structure of the roxithromycin impurity in the prior art is not clear, resulting in the fact that it is not clearly numbered in the pharmacopoeia, affecting its structural identification and the safety of clinical medication.

Method used

Provide a method for preparing roxithromycin impurity K, which is terminated by reacting erythromycin oxime with 1,2-bis(chloromethoxy)ethane under specific conditions, combined with glacial acetic acid, and then using lower alcohols or ketones as Crystallization solvent is used for crystallization and recrystallization, and finally purified by decolorization and pH adjustment by activated carbon to obtain O,O'-(ethylenedioxy) dimethylene dierythrin 9-(E)-oxime, used as a reference product Qualitative and quantitative analysis.

Benefits of technology

The high-purity preparation of roxithromycin impurities has been achieved, with a purity of more than 95%, filling the gap in research on roxithromycin impurities, improving the safety of medication, and providing high-precision qualitative and quantitative analysis tools.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994281A_ABST
    Figure CN118994281A_ABST
Patent Text Reader

Abstract

The invention provides a roxithromycin related substance as well as a preparation method and application thereof, and belongs to the technical field of erythromycin derivatives. The preparation method comprises the following steps: dissolving erythromycin oxime in a reaction solvent, adding an acid-binding agent at 0-10 DEG C, uniformly stirring, dropwise adding 1, 2-bis (chloromethoxy) ethane at-20-0 DEG C, reacting for 1-24 hours, adding glacial acetic acid to terminate the reaction, drying the reaction solvent by distillation under reduced pressure, dissolving the product dried by distillation under reduced pressure by taking C1-C4 lower alcohol and / or C3-C6 lower ketone as a crystallization solvent, adding activated carbon for decolorizing and filtering, adjusting the pH value to 10.5-11.5, and adding water for crystallization, and filtering, adding a recrystallization solvent and water into the solid, and recrystallizing to obtain the roxithromycin related substance. The roxithromycin related substance provided by the invention is high in purity and accurate in quantification and qualitation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a roxithromycin-related substance and a preparation method and application thereof, belonging to the technical field of erythromycin-derived substances. Background Art

[0002] The chemical name of Roxithromycin is: 9-[O-[(2-methoxyethoxy)-methyl]oxime]erythromycin, and its structure is shown in formula (I):

[0003]

[0004] Roxithromycin is a second-generation macrolide antibiotic, similar in structure to erythromycin, and is an ether oxime derivative of erythromycin. Its in vitro and antibacterial spectrum are also similar to those of erythromycin, but superior to erythromycin, with the characteristics of gastric acid resistance and good tissue permeability. It has antibacterial activity against Staphylococcus, Streptococcus, Neisseria gonorrhoeae, Chlamydia, Chlamydia pneumoniae, Legionella pneumophila, most Gram-positive anaerobic bacteria, most Clostridium difficile and about 50% of Bacteroides fragilis.

[0005] In the research on roxithromycin-related substances, including the United States Pharmacopoeia USP43 edition, the European Pharmacopoeia EP11.0 edition, and the Chinese Pharmacopoeia 2020 edition, the structural formula, relative retention peak time, content calculation correction factor and control limit of each impurity are introduced in detail. However, this impurity is not clearly numbered in the pharmacopoeia, and the impurity structure is not clear, which is not conducive to the identification of the structure and the safety of clinical use. Summary of the invention

[0006] In view of this, the present application first provides a roxithromycin related substance, which is O,O'-(ethylenedioxy)dimethylenedierythromycin 9-(E)-oxime, denoted as roxithromycin impurity K, and has the structural formula:

[0007]

[0008] The second purpose of the applicant is to provide a method for preparing the above-mentioned roxithromycin-related substances, using erythromycin oxime as a raw material.

[0009] Step 1: After erythromycin oxime is dissolved in a reaction solvent, an acid binding agent is added at 0 to 10°C, and after stirring evenly, 1,2-bis(chloromethoxy)ethane is added dropwise at -20 to 0°C for 1 to 24 hours, and glacial acetic acid is added to terminate the reaction.

[0010] The ratio of the weight of erythromycin oxime to the volume of the reaction solvent is 1:3-5,

[0011] The molar ratio of erythromycin oxime, acid binding agent and 1,2-bis(chloromethoxy)ethane is 1:1-2:0.5-2;

[0012] Step 2: evaporate the reaction solvent under reduced pressure, use C1-C4 lower alcohol and / or C3-C6 lower ketone as crystallization solvent to dissolve the product after evaporation under reduced pressure, add activated carbon to the refined product for decolorization and filtration, adjust the pH to 10.5-11.5, add water for crystallization, and filter.

[0013] The weight of the erythromycin oxime g: the volume of the crystallization solvent mL: the volume of water (i.e., the water in the "water crystallization" above) mL = 1:3-5:4-7.5;

[0014] Step 3: Filter the obtained solid and then add a recrystallization solvent and water for recrystallization to obtain O,O'-(ethylenedioxy)dimethylenedierythromycin 9-(E)-oxime.

[0015] The weight of the erythromycin oxime in g: the volume of the recrystallization solvent in mL: the volume of water (ie, water added during recrystallization) in mL = 1:2-5:3-7.5.

[0016] In the above process, the main reaction of erythromycin oxime and 1,2-bis(chloromethoxy)ethane is expressed as follows:

[0017]

[0018] In the above scheme:

[0019] The reaction solvent is dichloromethane, chloroform, DMF or ethyl acetate.

[0020] The acid binding agent is any one of potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide and sodium hydrogen.

[0021] The crystallization solvent is a mixture of C1-C4 lower alcohol and C3-C6 lower ketone, the C1-C4 lower alcohol is any one of methanol, ethanol, isopropanol and n-propanol, and the C3-C6 lower ketone is acetone or methyl ethyl ketone.

[0022] The 1,2-bis(chloromethoxy)ethane is commercially available or homemade. The method for making 1,2-bis(chloromethoxy)ethane is as follows: ethylene glycol is used as the starting material, a synthetic solvent and paraformaldehyde are added, thionyl chloride is added dropwise at -10 to 50°C for reaction, the temperature is kept for 1 to 24 hours, and the second solvent and excess thionyl chloride are evaporated under reduced pressure to obtain 1,2-bis(chloromethoxy)ethane. Preferably, the synthetic solvent is dichloromethane or chloroform, and the volume ratio of ethylene glycol to the synthetic solvent is 1:1 to 3. The molar ratio of ethylene glycol, paraformaldehyde, and thionyl chloride is 1:2:2 to 4.

[0023] The homemade process reaction is expressed as follows:

[0024]

[0025] The preparation process uses 1,2-bis(chloromethoxy)ethane with a symmetrical structure to react with erythromycin oxime to obtain a roxithromycin-related substance with a mirror image structure, namely O,O'-(ethylenedioxy)dimethylene diroxithromycin 9-(E)-oxime. The method is simple, and the product purity is as high as more than 95%. It can be used as a reference substance in the qualitative and quantitative analysis of roxithromycin impurities, which is beneficial to improving the drug safety of roxithromycin and filling the gap in the research of roxithromycin impurities.

[0026] The third purpose of the applicant is to provide the roxithromycin-related substance with the above structure as a reference substance for use in the qualitative and quantitative analysis of roxithromycin impurities. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0028] Figure 1 is the gas phase spectrum of 1,2-bis(chloromethoxy)ethane in this application;

[0029] Figure 2 The mass spectrum of the roxithromycin related substances in this application;

[0030] Figure 3 is the infrared spectrum of the roxithromycin related substances in this application;

[0031] Figure 4 The hydrogen spectrum of the roxithromycin related substances in this application ( 1 H-NMR);

[0032] Figure 5 For the roxithromycin related substances in this application 13 C-NMR carbon spectrum;

[0033] Figure 6 DEPT135° carbon spectrum of roxithromycin related substances in this application;

[0034] Figure 7 is the HSQC spectrum of the roxithromycin related substances in this application;

[0035] Figure 8 is the HMBC spectrum of the roxithromycin related substances in this application;

[0036] Fig. 9 1H-1H COSY spectrum of roxithromycin related substances in this application. DETAILED DESCRIPTION

[0037] In order to make the technical problems, technical solutions and beneficial effects to be solved by this application clearer, the technical solutions in the embodiments of this application will be further described in detail below in conjunction with the drawings in the embodiments of this application. It should be understood that the specific embodiments described herein are only used to explain this application and are not used to limit the technical solutions of this application. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0038] Example 1

[0039] The process of preparing 1,2-bis(chloromethoxy)ethane in this embodiment is as follows:

[0040] In a 500mL four-necked flask, add 50g (0.81mol) of ethylene glycol, 48g (about 1.62mol) of paraformaldehyde, and 50mL of dichloromethane. Stir and cool to -10°C, then add 200g (1.68mol) of thionyl chloride dropwise. After the addition is complete, slowly heat to 30°C and keep warm for 5h. Dichloromethane and excess thionyl chloride are evaporated under reduced pressure below 60°C to obtain 97.8g of liquid with a chromatographic purity of 91%.

[0041] Example 2

[0042] The process of preparing 1,2-bis(chloromethoxy)ethane in this embodiment is as follows:

[0043] In a 500mL four-necked flask, 50g (0.81mol) of ethylene glycol, 53g (about 1.62mol) of paraformaldehyde and 150mL of chloroform were added. The mixture was stirred and cooled to 0°C, and 300g (2.52mol) of thionyl chloride was added dropwise. After the addition was completed, the temperature was slowly raised to 50°C and kept warm for 2h. Chloroform and excess thionyl chloride were evaporated under reduced pressure below 60°C to obtain 105.5g of liquid with a chromatographic purity of 93%.

[0044] The 1,2-bis(chloromethoxy)ethane prepared in Examples 1 and 2 was subjected to gas phase detection, and the results were as follows: Figure 1 As shown (represented by Example 2), it is confirmed that the obtained product is indeed 1,2-bis(chloromethoxy)ethane.

[0045] The above examples respectively use different synthetic solvents, dichloromethane and chloroform, to obtain 1,2-bis(chloromethoxy)ethane. Relatively speaking, when chloroform is used as the synthetic solvent, the purity of the product is higher.

[0046] Example 3

[0047] The process of preparing the related substances of Roxithromycin in this embodiment is as follows:

[0048] Add 40 g (0.0534 mol) of erythromycin oxime and 200 mL of dichloromethane into a 500 mL four-necked flask, stir and cool to 0°C, add 6 g (0.1069 mol) of potassium hydroxide, stir for 30 min, and cool to 0°C; add 1,2-bis(chloromethoxy)ethane 17 g (0.1069 mol) dropwise, keep the reaction warm for more than 2 h, and add 2 mL of glacial acetic acid to terminate the reaction.

[0049] Concentrate to dryness under reduced pressure below 70°C, add 120mL of methanol and heat to dissolve, add 0.5g of activated carbon, stir for 30min, filter while hot, warm the filtrate to 40°C, slowly drop 20% sodium hydroxide solution under stirring, adjust pH to 10.5, warm to complete dissolution, cool to 35°C, add 160mL of purified water, stir for 1h, cool to below 20°C, filter, wash the filter cake with a small amount of purified water to obtain a white solid.

[0050] Add 100 mL of methanol to the above white solid and heat to dissolve, cool to 35°C, add 150 mL of purified water dropwise, stir for 1 h, cool to below 20°C, filter, and vacuum dry to obtain 29.5 g of white solid with a chromatographic purity of 95.4%.

[0051] Example 4

[0052] The process of preparing the related substances of Roxithromycin in this embodiment is as follows:

[0053] Add 40 g (0.0534 mol) of erythromycin oxime and 200 mL of chloroform into a 500 mL four-necked flask, stir and cool to 10 °C, add 4.2 g (0.1050 mol) of sodium hydroxide, stir for 30 min, and cool to 0 °C; add 1,2-bis(chloromethoxy)ethane 16.7 g (about 0.1050 mol) dropwise, keep the reaction warm for more than 2 h, and add 2 mL of glacial acetic acid to terminate the reaction.

[0054] Concentrate to dryness under reduced pressure below 70°C, add 120mL ethanol and heat to dissolve, add 0.5g activated carbon, stir for 30min, filter while hot, heat the filtrate to 40°C, slowly drop 20% sodium hydroxide solution under stirring, adjust pH to 10.5, heat until completely dissolved, cool to 45°C, keep warm and stir for 30min. Cool to 30°C, add 160mL purified water, stir for 1h, cool to below 20°C, filter, wash the filter cake with a small amount of purified water to obtain a white solid.

[0055] The above white solid was dissolved in 100 mL of ethanol by heating, the filtrate was heated to 40°C, 150 mL of purified water was added dropwise, stirred for 1 h, cooled to below 20°C, filtered, and vacuum dried to obtain 28.2 g of white solid with a chromatographic purity of 94.9%.

[0056] Example 5

[0057] The process of preparing the related substances of Roxithromycin in this embodiment is as follows:

[0058] Add 40 g (0.0534 mol) of erythromycin oxime and 120 mL of DMF into a 500 mL four-necked flask, stir and cool to 0°C, add dropwise 11.3 g (0.0586 mol) of 28% sodium methoxide solution, stir for 30 min, and cool to 0°C; add dropwise 9.3 g (0.0585 mol) of 1,2-bis(chloromethoxy)ethane, keep warm for 2 h, and add 2 mL of glacial acetic acid to terminate the reaction.

[0059] Concentrate to dryness under reduced pressure below 70°C, add 120mL acetone and heat to dissolve, add 0.5g activated carbon, stir for 30min, filter while hot, heat the filtrate to 40°C, slowly drop 20% sodium hydroxide solution under stirring, adjust pH to 11, heat until completely dissolved, cool to 45°C, keep warm and stir for 30min. Cool to 30°C, add 160mL purified water, stir for 1h, cool to below 20°C, filter, wash the filter cake with a small amount of purified water to obtain a white solid.

[0060] The above white solid was dissolved in 100 mL of acetone at elevated temperature, the filtrate was heated to 40°C, 150 mL of purified water was added dropwise, stirred for 1 h, cooled to below 20°C, filtered, and vacuum dried to obtain 31.5 g of a white solid with a chromatographic purity of 95.8%.

[0061] The vacuum baked product obtained in Example 5 was used as a representative for product confirmation. Mass spectrometry analysis (see Figure 2 ) determined its molecular weight to be 1583.99, which is consistent with the inferred molecular formula C 78 H 142 N4O 28 be consistent.

[0062] In further testing, the infrared absorption spectrum of the product obtained in Example 5 is as follows Figure 3 As shown (IR), nuclear magnetic resonance hydrogen spectrum as Figure 4 As shown ( 1 H-NMR), carbon spectra such as Figure 5 , Figure 6 As shown ( 13 C-NMR, DEPT135°), and Figure 7 HSQC Figure 8 HMBC Fig. 9 of 1 H- 1 The relative position relationship of each atom in the 2D NMR spectrum corresponding to H COSY was further confirmed, and the final structure of the product was determined to be:

[0063]

[0064] The above Examples 3, 4 and 5 respectively provide the preparation of roxithromycin-related substances under different crystallization solvents, recrystallization solvents and acid-binding agents, and the purity of the products is maintained above 95%, which confirms the feasibility of the route of the present application.

[0065] The roxithromycin related substance prepared by the above scheme is used for the qualitative and quantitative analysis of roxithromycin. The related substance has a clear structure and a purity of more than 95%, which gives the qualitative and quantitative analysis a corresponding high precision, and is conducive to improving the drug safety of roxithromycin. The preparation process of the related substance is simple and easy to operate, which effectively reduces the technical threshold and cost investment of the reference substance.

[0066] The above-mentioned embodiments only express several feasible implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention, and the embodiments are not used to limit the scope of protection in the claims of the present invention. For ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, and all equivalent implementations or changes that do not depart from the present invention should be included in the technology of the present invention.

Claims

1. A roxithromycin related substance, characterized in that: Roxithromycin related substances are O , O' -(ethylenedioxy)dimethylenedioxyerythromycin 9-( E )-oxime, whose structural formula is: .

2. A method for preparing the roxithromycin related substance according to claim 1, characterized in that: Using erythromycin oxime as raw material, Step 1: After erythromycin oxime is dissolved in the reaction solvent, an acid binding agent is added at 0-10°C, and after stirring evenly, 1,2-bis(chloromethoxy)ethane is added dropwise at -20-0°C for 1-24 hours, and glacial acetic acid is added to terminate the reaction. The ratio of the weight of erythromycin oxime to the volume of the reaction solvent is 1:3-5. The molar ratio of erythromycin oxime, acid binding agent and 1,2-bis(chloromethoxy)ethane is 1:1-2:0.5-2; Step 2, evaporating the reaction solvent under reduced pressure, using C1~C4 lower alcohol and / or C3~C6 lower ketone as a crystallization solvent, dissolving the product after evaporation under reduced pressure, adding activated carbon to decolorize the dissolved liquid, filtering it, adjusting the pH to 10.5~11.5, adding water to crystallize, filtering, The weight of the erythromycin oxime g: the volume of the crystallization solvent mL: the volume of water mL=1:3~5:4~7.5; Step 3: Filter the solid obtained, add a recrystallization solvent and water for recrystallization to obtain O , O' -(ethylenedioxy)dimethylenedioxyerythromycin 9-( E )-oxime, The weight of the erythromycin oxime (g): the volume of the recrystallization solvent (mL): the volume of water (mL) = 1:2-5:3-7.

5.

3. A method for preparing a roxithromycin related substance according to claim 2, characterized in that: The first solvent is dichloromethane, chloroform, DMF or ethyl acetate.

4. A method for preparing a roxithromycin related substance according to claim 2, characterized in that: The acid binding agent is any one of potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide and sodium hydrogen.

5. A method for preparing a roxithromycin related substance according to claim 2, characterized in that: The crystallization solvent is a mixture of C1~C4 lower alcohol and C3~C6 lower ketone, the C1~C4 lower alcohol is selected from any one of methanol, ethanol, isopropanol, and n-propanol, and the C3~C6 lower ketone is acetone or methyl ethyl ketone.

6. A method for preparing a roxithromycin related substance according to any one of claims 2 to 5, characterized in that, The preparation method of 1,2-bis(chloromethoxy)ethane is as follows: ethylene glycol is used as a starting material, a synthetic solvent and polyformaldehyde are added, thionyl chloride is added dropwise at -10 to 50°C for reaction, the temperature is kept for 1 to 24 hours, and the solvent and excess thionyl chloride are evaporated under reduced pressure to obtain 1,2-bis(chloromethoxy)ethane.

7. A method for preparing a roxithromycin related substance according to claim 6, characterized in that: The synthetic solvent is dichloromethane or chloroform, and the volume ratio of ethylene glycol to the synthetic solvent is 1:1-3.

8. A method for preparing a roxithromycin related substance according to claim 6, characterized in that: The molar ratio of the ethylene glycol, paraformaldehyde and thionyl chloride is 1:2:2-4.

9. An application of the roxithromycin related substance according to claim 1, characterized in that: Roxithromycin related substances are used as reference substances for qualitative and quantitative analysis of roxithromycin impurities.